J Drugs Dermatol. 2020 Jul 1;19(7):719-724. doi: 10.36849/JDD.2020.5201.
Background: There is currently an unmet need for the treatment of women with central centrifugal cicatricial alopecia (CCCA). Objective: To evaluate the safety and efficacy of Clobetasol propionate 0.05% emollient foam for the treatment of women with CCCA. Methods: Adult women of African descent that presented with clinical evidence of early CCCA were enrolled (N=30). Clobetasol propionate 0.05% emollient foam was applied daily in an open-label fashion. Safety and efficacy assessments were performed at weeks 2, 6, 12, and 14. Results: Subjects achieved substantial improvements in pruritus, pain, tenderness, erythema and scaling. Scalp biopsies revealed considerable improvements in severe inflammation and perifollicular edema. Overall, clobetasol propionate 0.05% emollient foam was well-tolerated. Limitations: This was a nonrandomized, open-label study. Enrollment was limited to subjects with clinically mild CCCA. Conclusion: Subjects with CCCA that applied topical clobetasol propionate 0.05% emollient foam to their scalp daily demonstrated continuous clinical improvement throughout the 14-week study. ClinicalTrials.gov Identifier: NCT01111981 J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.5201.
目前，针对女性中枢性离心性瘢痕性脱发（CCCA）的治疗存在未满足的需求。目的：评估氯倍他索丙酸 0.05% 软膏剂泡沫剂治疗 CCCA 女性患者的安全性和疗效。方法：纳入具有早期 CCCA 临床证据的成年非裔女性患者（N=30）。采用开放性标签设计，每日使用氯倍他索丙酸 0.05% 软膏剂泡沫剂。在第 2、6、12 和 14 周进行安全性和疗效评估。结果：患者的瘙痒、疼痛、触痛、红斑和鳞屑均有显著改善。头皮活检显示严重炎症和毛囊周围水肿有明显改善。总体而言，氯倍他索丙酸 0.05% 软膏剂泡沫剂耐受性良好。局限性：这是一项非随机、开放性标签研究。仅纳入临床轻度 CCCA 的患者。结论：每日将外用氯倍他索丙酸 0.05% 软膏剂泡沫剂应用于头皮的 CCCA 患者在整个 14 周研究中持续显示出临床改善。ClinicalTrials.gov 标识符：NCT01111981 J 皮肤病药物杂志。2020;19(7)：doi:10.36849/JDD.2020.5201。
